Indapamide

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Retrieved on: 
Sunday, April 7, 2024
Research, FDA, Clinical Trials, Cardiology, Biotechnology, Managed Care, Health, Pharmaceutical, Science, Blood pressure, Medication, Indapamide, Risk, Patient, Month, SBP, ABPM, American College, Olmesartan, Injection, Safety, RNA interference, Therapy, AGT, ACC, Amlodipine, Cardiomyopathy, Hypertension, Pharmaceutical industry

Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.

Key Points: 
  • Zilebesiran is an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension with the potential for biannual dosing.
  • The results were presented today as a late-breaking clinical trial at the 2024 American College of Cardiology (ACC) Annual Scientific Session.
  • The Company previously announced positive topline results from the KARDIA-2 study in March 2024.
  • “Although many effective oral treatments are available, a large proportion of patients with hypertension are not managed to guideline-recommended targets.

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Retrieved on: 
Tuesday, March 5, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Blood pressure, DBP, Amlodipine, Roche, Month, Safety, Glomerular filtration rate, ABPM, Trial of the century, Cardiology, Indapamide, AGT, Hypertension, American College, SBP, EGFR, Patient, Angiotensin, DB, Alnylam Pharmaceuticals, Medication, RNA interference, Pharmaceutical industry

Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.

Key Points: 
  • Zilebesiran demonstrated an encouraging safety and tolerability profile when added to these standard of care antihypertensives.
  • “We are thrilled that a single dose of zilebesiran achieved clinically significant, additional reductions in systolic blood pressure when administered to patients who are not adequately controlled with commonly prescribed antihypertensives,” said Simon Fox, Ph.D., Vice President, Zilebesiran Program Lead at Alnylam.
  • “These KARDIA-2 results, showing durable additional levels of blood pressure reduction on top of what is achieved by standard of care first-line antihypertensives with an encouraging safety profile, reinforce our confidence in zilebesiran’s differentiated profile.
  • The primary endpoint is the change from baseline in mean SBP at Month 3, assessed by 24-hour ABPM.

WELL Health Achieves Great Place to Work® Certification, and Strengthens Data Security with ISO 27001 Certifications

Retrieved on: 
Tuesday, December 19, 2023
Culture, Learning, Trust, Consultant, Mindfulness, ESG, Certification, Empowerment, WELL, University, Mental health, Workplace, Yoga, ISO, TSX, Patient, Indapamide, Environment, Nursing

For more information on WELL's Great Place to Work® certification, please visit the WELL page on the Great Place to Work® website here .

Key Points: 
  • For more information on WELL's Great Place to Work® certification, please visit the WELL page on the Great Place to Work® website here .
  • This achievement not only solidifies WELL's commitment to data security but also enhances their market positioning where data security is a key concern.
  • The ISO 27001 certification of WELL's portfolio companies also exemplifies the "Safeguarding Patient Data" pillar of WELL's ESG strategy.
  • This reflects the Company's dedication to data security as a core aspect of corporate responsibility in the digital health sector.

WELL Health Announces Record Patient Visits and Total Care Interactions for Q3-2023 Resulting in Record Quarterly Revenue

Retrieved on: 
Tuesday, November 7, 2023
Growth, Alliance for Natural Health USA, WELL Health Technologies, MCI, Family, Travel Technology Interactive, Indapamide, Acquisition, WELL, RADAR, Hospital, Nursing, Wisp

WELL achieved a total of 1,576,701 Total Care Interactions3 in Q3-2023, a year-over-year increase of ~27% compared to Q3-2022 and representing ~6.3 million Total Care Interactions on an annualized run-rate basis.

Key Points: 
  • WELL achieved a total of 1,576,701 Total Care Interactions3 in Q3-2023, a year-over-year increase of ~27% compared to Q3-2022 and representing ~6.3 million Total Care Interactions on an annualized run-rate basis.
  • Total Care Interactions are defined as Patient Visits in addition to Technology Interactions and Billed Provider Hours.
  • Diagnostic patient visits performed by MyHealth and False Creek Wellness are now included in Canadian Patient visits, while Wisp's asynchronous patient visits are now included in US Patient visits.
  • US Patient Visits include all patient visits, as defined in Footnote 1, facilitated by WELL Health USA and its subsidiaries.

Pharmascience Canada launches a new generic drug to treat hypertension

Retrieved on: 
Tuesday, September 5, 2023
Blood pressure, Hypertension, HD, Perindopril, Tablet, Patient, ACE, Safety, Indapamide, Pharmaceutical industry, Copper, Pharmascience

pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine/ indapamide) are a combination of perindopril erbumine, an angiotensin converting enzyme (ACE) inhibitor, and indapamide, a chlorosulphamoyl diuretic.

Key Points: 
  • pms-PERINDOPRIL-INDAPAMIDE (perindopril erbumine/ indapamide) are a combination of perindopril erbumine, an angiotensin converting enzyme (ACE) inhibitor, and indapamide, a chlorosulphamoyl diuretic.
  • pms-PERINDOPRIL-INDAPAMIDE comes in the following dosage forms:
    Tablets of 2 mg perindopril erbumine/ 0.625 mg indapamide.
  • pms-PERINDOPRIL-INDAPAMIDE is a generic equivalent to Coversyl® Plus, Coversyl® Plus LD and Coversyl® Plus HD and has the same safety and efficacy as Coversyl®.
  • - mentioned Mike Dutton, Vice President, and General Manager of Pharmascience Canada.

WELL Health Announces Record Patient Visits and Interactions for Q2-2023 Resulting in Record Quarterly Revenue

Retrieved on: 
Thursday, August 3, 2023
Alliance for Natural Health USA, Travel Technology Interactive, Tax, WELL, EBITDA, Investment, Indapamide, Growth, Depreciation, WELL Health Technologies, Adjustment, Family, Pharmaceutical industry, Nursing, Wisp

Patient visits are defined by any interaction a patient has with a WELL practitioner through all sources and channels.

Key Points: 
  • Patient visits are defined by any interaction a patient has with a WELL practitioner through all sources and channels.
  • Patient Interactions are defined as Patient Visits plus Technology Interactions.
  • Diagnostic patient visits performed by MyHealth and False Creek Wellness are now included in Canadian Patient visits, while Wisp's asynchronous patient visits are now included in US Patient visits.
  • US Patient Visits include all patient visits, as defined in Footnote 1, facilitated by WELL Health USA and its subsidiaries.

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2

Retrieved on: 
Wednesday, July 12, 2023
Telmisartan, Diabetes, Disability, ICTU, Indapamide, Hypertension, Patient, Amlodipine, Death, Imperial College London, Safety, Pharmaceutical industry, Novel

George Medicines’ mission is to extend and improve the lives of the millions of people suffering from non-communicable cardiometabolic diseases – the world’s leading causes of death and disability, including hypertension and diabetes.

Key Points: 
  • George Medicines’ mission is to extend and improve the lives of the millions of people suffering from non-communicable cardiometabolic diseases – the world’s leading causes of death and disability, including hypertension and diabetes.
  • Globally, over a billion people worldwide have hypertension but fewer than one in five have the condition under control.
  • GMRx2 is formulated in novel, patent-protected low and ultra-low doses, to be a simple, go-to solution to reach targeted blood pressure control across different patient types.
  • Dr. Karl Roberts, Chief Operating Officer of George Medicines, said: “The progress of this Phase III programme is a huge testament to the dedication of the team and our partners working to bring GMRx2 to patients.

WELL Health Reports Record Patient Visits and Interactions for Q1-2023 Driven by Strong Organic Growth

Retrieved on: 
Thursday, May 4, 2023
Travel Technology Interactive, WELL, CRH, NPS, Indapamide, Growth, Family, Nursing, Wisp

Growth in US Patient Visits was primarily driven by organic growth in Circle Medical and Wisp businesses, in addition to acquisitions by CRH over the past year.

Key Points: 
  • Growth in US Patient Visits was primarily driven by organic growth in Circle Medical and Wisp businesses, in addition to acquisitions by CRH over the past year.
  • Organic growth continues to be a significant contributor to our overall growth, with Q1 being the 5th consecutive quarter of double-digit organic growth.
  • Diagnostic patient visits performed by MyHealth and False Creek Wellness are now included in Canadian Patient visits, while Wisp's asynchronous patient visits are now included in US Patient visits.
  • Technology Interactions does not include the many millions of patient interactions supported by WELL's EMR Group or family of digital health apps such as the OceanMD patient engagement platform.

WELL Makes Investment in doctorly and Launches Strategic Alliance, to tech enable German Doctors

Retrieved on: 
Wednesday, March 1, 2023
Storm, VC, TSX, Gesellschaft mit beschränkter Haftung, WELL, Software, Patient, Growth, Li Ka-shing, Traction, Venture, Friends, Delta Force, Airline, Pharmaceutical industry, Nursing, Indapamide

WELL Ventures, the venture capital arm of WELL, is leading an investment round in doctorly alongside Horizons Ventures and a syndicate of leading venture capital firms.

Key Points: 
  • WELL Ventures, the venture capital arm of WELL, is leading an investment round in doctorly alongside Horizons Ventures and a syndicate of leading venture capital firms.
  • As part of the investment and strategic alliance agreements, the Ocean platform, created by WELL's wholly owned subsidiary, CognisantMD, will be used as the exclusive booking and practice engagement platform for doctorly.
  • WELL and doctorly will also work together on future projects within the German healthcare market following this investment round.
  • This investment round makes doctorly the first company with regulatory approval to sell its software in Germany to receive VC funding."

BioLink Life Sciences, Charak Foundation and KARE Biosciences Announce contract for developing a novel treatment of COVID pneumonia and prevention of long COVID

Retrieved on: 
Wednesday, October 5, 2022
Time-invariant system, D2, Atherosclerosis, Sepsis, United States Department of Health and Human Services, Breathe Me, Biomedical Advanced Research and Development Authority, Disease, Hospital, Sickle cell disease, Coagulation, Indapamide, Pandemic, Spironolactone, Development, Human services, Pulmonary hypertension, Pneumonia, Severe acute respiratory syndrome coronavirus 2, Education, COVID, Allergic rhinitis, Medicine, Patient, Thrombosis, Open philanthropy (doctrine), Ogletree, Degenerative disease, Immune system, Administration, Company, PGD2, Health, Hypoxemia, Department, Blood, A2, Biolink zones, Eplerenone, Prostaglandin D2, Thromboxane A2, Philanthropy, COVID-19, Mouth, Silicosis, Pharmaceutical industry, Ramatroban

BioLink's $750,000 contract from BARDA complements a multimillion dollar grant from Open Philanthropy to the Charak Foundation.

Key Points: 
  • BioLink's $750,000 contract from BARDA complements a multimillion dollar grant from Open Philanthropy to the Charak Foundation.
  • Ramatroban has been approved and used in Japan for over 20 years for treatment of allergic rhinitis by twice daily oral administration.
  • BioLink Life Sciences is a North Carolina based clinical research company that develops novel, proprietary pharmaceutical products via multiple regulatory pathways.
  • KARE Biosciences is also developing a novel, antihypertensive combination of indapamide, the best-in-class thiazide-like diuretic, in combination with a mineralocorticoid receptor antagonist (spironolactone or eplerenone).